Vaxcyte Inc (PCVX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $57.78 (-4.29%), Market cap $6.99B, 52-week low–high $29.67 ~ $63.04.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel prec
Financial statements, price targets, institutional (13F) holdings and related news for Vaxcyte Inc are updated in real time on BlackAll Trade.
Vaxcyte Inc trades at $57.78 (-4.29%). Real-time quotes and charts are available on BlackAll Trade.
Vaxcyte Inc has a market cap of about $6.99B.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-